Date: 6/25/2007 9:00:00 AM
West Bridgewater, MA, June 25, 2007 – Pressure BioSciences, Inc. (NASDAQ: PBIO) (“PBI”) today announced that it has launched its first pressure cycling technology (PCT)-dependent research-use only kit. Called ProteoSolveLRS, the kit is intended to help the thousands of scientists worldwide who have the difficult task of extracting proteins from important lipid-rich samples. ProteoSolveLRS was launched on Saturday, June 23rd at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois.
On June 6, 2007, PBI announced the development of a novel, potentially revolutionary PCT-dependent method for the safe, rapid, efficient, and reproducible extraction of proteins from lipid-rich samples, including adipose and brain tissues, organelles, and membrane preparations. Proteomic analysis of such samples is widely used in the study of diabetes, cancer, ALS, heart disease, and a number of other serious human disorders related to obesity. The Company believes that its PCT-dependent method of protein extraction from lipid-rich samples offers significant advantages over current extraction techniques, especially the ability to use certain organic solvents instead of harsh detergents in the extraction process.
The Company believes that obesity is an epidemic clinical condition directly related to roughly 300,000 deaths per year in the US, and associated with an increased risk for a number of serious health conditions, particularly diabetes. A recent study by the National Changing Diabetes Program (NCDP) indicated that 18 of 21 US federal agencies had a budgetary influence impact on diabetes, that one out of eight US federal health care dollars is spent treating people with diabetes, and that of the $645 billion estimated in total US health care spending in 2005, the US spent approximately 12%, or $79.7 billion, related to diabetes. The study’s research team suggested that there were “many missed opportunities for the federal government to enhance its impact on diabetes prevention, detection, treatment, and management of complications.”
Dr. Nathan P. Lawrence, Vice President of Marketing and Sales of PBI, said: “ProteoSolveLRS combines specific buffers, solvents, PULSE Tubes (PCT processing vials), and instructions in a single box (”kit”). All the researcher needs to do is to purchase or lease the Barocycler instrument and purchase the kit from PBI and they will have everything they need to enhance their protein extraction from lipid-rich samples.”
Mr. Richard T. Schumacher, Founder, President, and CEO of PBI, commented: “We strongly believe that our novel, patent-pending, PCT-dependent method for the detergent-free extraction of proteins from lipid-rich samples will benefit the thousands of researchers around the world who are working on new approaches for the prevention, detection, and treatment of diseases related to obesity, including diabetes, heart disease, stroke, and cancer. As recently announced, we are aggressively expanding our sales team and other sales capabilities at this time. Over the coming months, we plan to focus a majority of these additional capabilities in areas of research where lipid-rich samples are currently being used, as we believe that these areas offer tremendous potential for a significant return on investment for PBI.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 U.S. and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.
About Southern California Investment Association:
SCIA National Small Cap Syndicate is a comprehensive national organization developed to facilitate stock support and capital formation for small and emerging-growth companies. The alliance consists of almost 200 influential member firms plus associates including NASD broker/dealers, bankers, investment advisors, analysts, market makers, venture capitalists, fund managers, media and accredited investors. The syndicate provides equity and debt financing, institutional and retail stock support, market making, and mergers and more. See http://www.sciaonline.org.
Forward-Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2006, in the Company's Annual Report on Form 10-KSB, as amended, for the year ended December 31, 2005, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law
Visit us at our website http://www.pressurebiosciences.com
CONTACT:
Pressure BioSciences, Inc.
Investor Contacts:
Richard T. Schumacher, President & CEO
Edward H. Myles, Sr. Vice President of Finance & CFO
(508) 580-1818
© 2003-2007 Accelerize New Media, Inc. All rights reserved.
SECFilings.com is not affiliated with or approved by the SEC and shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Replication or redistribution of SECFilings.com content is expressly prohibited without the prior written consent of Accelerize New Media, Inc.